Biofrontera (NASDAQ:BFRI) Upgraded by Zacks Research to “Hold” Rating

Biofrontera (NASDAQ:BFRI) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

BFRI has been the subject of several other reports. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen raised Biofrontera to a “hold” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Biofrontera Price Performance

BFRI opened at $1.22 on Monday. Biofrontera has a one year low of $0.55 and a one year high of $1.27. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.20 and a quick ratio of 1.09. The company’s 50 day simple moving average is $1.03 and its 200-day simple moving average is $0.96. The stock has a market capitalization of $15.62 million, a P/E ratio of -1.26 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.29). Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.The company had revenue of $10.08 million during the quarter, compared to the consensus estimate of $10.25 million. Sell-side analysts anticipate that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC boosted its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the period. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.